about
Goblet cell carcinoids of the appendixTrefoil factors in inflammatory bowel diseaseEffects of resveratrol in experimental and clinical non-alcoholic fatty liver diseaseSmall intestinal transit in patients with liver cirrhosis and portal hypertension: a descriptive studyAge-dependency of galactose elimination capacity in healthy children and children with chronic liver diseaseHighest frequencies of interleukin-22-producing T helper cells in alcoholic hepatitis patients with a favourable short-term course.Goblet cell carcinoids: characteristics of a Danish cohort of 83 patients.Markers of Collagen Remodeling Detect Clinically Significant Fibrosis in Chronic Hepatitis C Patients.Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition.Alcoholic Hepatitis Markedly Decreases the Capacity for Urea SynthesisRandomized crossover study in patients with neuroendocrine tumors to assess patient preference for lanreotide Autogel(®) given by either self/partner or a health care professional.Rectal Mechano-sensory Function in Patients with Carcinoid Diarrhea.Anti-CD163-dexamethasone conjugate inhibits the acute phase response to lipopolysaccharide in rats.MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C.The influence of preconditioning on metabolic changes in the pig liver before, during, and after warm liver ischemia measured by microdialysis.Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.No difference in portal and hepatic venous bacterial DNA in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt insertion.Diagnosis and treatment of bronchopulmonary neuroendocrine tumours: State of the art.Effects of lifestyle intervention on soluble CD163, a macrophage activation marker, in patients with non-alcoholic fatty liver disease.Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas.A descriptive cross-sectional study of pain in patients with neuroendocrine tumors.Soluble programmed death-1 levels are associated with disease activity and treatment response in patients with autoimmune hepatitis.Reduced sCD36 following weight loss corresponds to improved insulin sensitivity, dyslipidemia and liver fat in obese children.Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease.Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study.IFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis.Combination of radiofrequency ablation with transarterial chemoembolization for treatment of hepatocellular carcinoma: experience from a Danish tertiary liver center.Isolated congenital hepatic fibrosis associated with TMEM67 mutations: report of a new genotype-phenotype relationship.Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF).A MUTYH germline mutation is associated with small intestinal neuroendocrine tumors.Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma.Antibody-Directed Glucocorticoid Targeting to CD163 in M2-type Macrophages Attenuates Fructose-Induced Liver Inflammatory Changes.Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.Effect of resveratrol on experimental non-alcoholic steatohepatitis.Regulation of urea synthesis during the acute-phase response in rats.Quantitative histological assessment of hepatic ischemia-reperfusion injuries following ischemic pre- and post-conditioning in the rat liver.Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma.Propranolol treatment of portal hypertension in cirrhosis patients is better the higher the untreated pressure: a single-centre prospective experience.Insulin-like growth factor-I concentration and risk of prostate cancer: results from the European Prospective Investigation into Cancer and Nutrition.The soluble mannose receptor (sMR) is elevated in alcoholic liver disease and associated with disease severity, portal hypertension, and mortality in cirrhosis patients.
P50
Q21284834-542A9D86-1973-4E21-95A7-6AC88F91C53FQ27015771-691784A7-0524-4A5C-AA08-43E31F68242CQ33563877-AD09AFD4-EF61-410F-9D32-8BEC188FD3C5Q34502451-73E99007-B7EE-493C-863B-B8D01F0056DDQ34544934-DEDFFA8E-8674-4B37-979A-A61156061BC7Q34571578-A18B0149-B119-475F-B2AB-1B7BEC819019Q35074655-B186FEDF-781E-4142-8D74-63CBC1033B0FQ35787865-5ABA7A6A-209C-40C0-8951-CF77DB470424Q35835118-AEF45F58-3FB4-41D4-BCC5-AC80F8BFCB6FQ36068221-ED3D7F61-D181-464E-85C0-0DDB00BE0086Q36358185-EEB61BE1-A7B6-4B31-80EC-75B1ABAA2771Q36762652-C51C31DE-FF99-42AC-A4EB-DD57D2DDF6CCQ37014721-DD05F5EC-733A-4628-AD97-BEACD6450AB5Q37264708-4867652E-93AC-43FD-9A62-6A84B8F6D2F6Q37266055-2E1638DF-D0D9-4DA7-B0F6-1EBD11A5D608Q38241601-09C49A95-DF11-40B5-B89F-D623C450B896Q38314866-0B005599-B8A5-4A6D-8234-B01E0A6C705BQ38557054-7D14EEB5-0E23-49AA-AD8A-764C438CD65EQ38675714-80E04083-D0D2-4F61-9D29-848516442979Q38776280-57D2A627-8C04-43FF-9125-3652E9CDB7FFQ39144954-2D8A9FEE-58F4-4D6C-9709-85A6FE1BCB97Q39413389-673B0116-B8DA-4C30-813D-1DF1917875D1Q39702732-ED43F28D-1894-4DFC-A580-28B842C2D764Q40122113-D99E20EC-81B9-4826-9674-ECA8CF451123Q40200855-2120E65A-93C1-4DED-AE0F-D1EFC8FA9979Q40258100-68CB7F6B-749B-47F5-9E69-5BE8ACAEB657Q40571203-F4BA0214-1DC6-41FE-B0DD-580211D49694Q40981091-06CED31D-C71D-41DD-A9C2-80DEB266E1BFQ41071756-D557112E-18C8-4686-A1C7-41110C179FD5Q41127338-8FDCF674-316C-4920-AE6E-005E1AE47617Q41139490-A7066121-1F88-4178-9907-476A478C9475Q42284206-75526BF5-98D2-4A6D-9E4D-E1E3BDF63BE3Q42699372-F4EE9CBF-88D9-4713-9A22-651A4EE664D1Q42702171-4B80D566-EA4C-4687-A9A8-314AE1C2E30AQ43512192-7F83B987-A541-41CB-9DE6-3145EA36FC03Q45789278-BBB121DF-1E16-439F-BD3F-23CD0408EC91Q46513952-13205CD2-FF57-4788-B2F2-637963B050D1Q46636982-501D88A8-5034-423C-AF57-99DBF070ED70Q47094089-B17E06BA-0AFF-4EF5-BA4D-CD9E2A43F212Q47132141-0D1272C4-39C4-4451-9827-BBCAFDA8BAD3
P50
description
Deens onderzoeker
@nl
dänischer Mediziner
@de
hulumtues
@sq
researcher
@en
taighdeoir
@ga
հետազոտող
@hy
name
Henning Grønbæk
@ast
Henning Grønbæk
@bar
Henning Grønbæk
@br
Henning Grønbæk
@ca
Henning Grønbæk
@ceb
Henning Grønbæk
@co
Henning Grønbæk
@da
Henning Grønbæk
@de
Henning Grønbæk
@en
Henning Grønbæk
@es
type
label
Henning Grønbæk
@ast
Henning Grønbæk
@bar
Henning Grønbæk
@br
Henning Grønbæk
@ca
Henning Grønbæk
@ceb
Henning Grønbæk
@co
Henning Grønbæk
@da
Henning Grønbæk
@de
Henning Grønbæk
@en
Henning Grønbæk
@es
altLabel
Groenbaek h
@en
Gronbaek h
@en
Gronbiek h
@en
Grøenbæk,
@en
prefLabel
Henning Grønbæk
@ast
Henning Grønbæk
@bar
Henning Grønbæk
@br
Henning Grønbæk
@ca
Henning Grønbæk
@ceb
Henning Grønbæk
@co
Henning Grønbæk
@da
Henning Grønbæk
@de
Henning Grønbæk
@en
Henning Grønbæk
@es
P106
P1153
7004064278
P21
P27
P31
P3835
henning-gronbaek
P496
0000-0001-8998-7910